Lipid Lowering Therapy After Cardiac Rehabilitation LLT-R-Registry
LLT-R-Registry
Adherence to Lipid Lowering Therapy After Cardiac Rehabilitation (LLT-Rehabilitation-Registry)
1 other identifier
observational
1,100
1 country
1
Brief Summary
The most important drugs for evidence based lipid lowering treatment (LLT) in CHD are statins. All patients with established CHD should be treated with statins irrespective of low density lipoprotein (LDL) cholesterol (LDL-C) levels. The goals of treatment are LDL-C below 1.8 mmol/L (70 mg/dL) or 50% LDL-C reduction when target level cannot be reached. Unfortunately, several patients cannot achieve treatment targets also related to the serious problem of adherence to therapy, which includes also LLT.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2016
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 8, 2016
CompletedFirst Posted
Study publicly available on registry
April 22, 2016
CompletedStudy Start
First participant enrolled
May 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2020
CompletedAugust 28, 2019
March 1, 2019
3.1 years
April 8, 2016
August 27, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Data collection (Adherence to lipid lowering therapy after cardiac rehabilitation)
Adherence to lipid lowering therapy after cardiac rehabilitation
12 Months
Eligibility Criteria
All patients with CHD, who will be admitted for cardiac rehabilitation to the participating German rehabilitation clinics and in whom LLT is indicated will be included. Written informed consent will be obtained from each participant. Beginning of the study is 1st May 2016, the inclusion of the last patient is expected on 30th April 2016. Follow-up: at 3 and 12 months, respectively, inclusion of 100 participants per clinic is expected.
You may qualify if:
- Lipid lowering therapy after cardiac rehabilitation
You may not qualify if:
- Inability or refusal to give written informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Paracelsus Harz Clinic Bad Suderode.lead
- KKS Netzwerkcollaborator
Study Sites (1)
Paracelsus Harz Clinic Bad Suderode
Quedlinburg, Saxony-Anhalt, 06485, Germany
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 12 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 8, 2016
First Posted
April 22, 2016
Study Start
May 1, 2016
Primary Completion
June 1, 2019
Study Completion
September 1, 2020
Last Updated
August 28, 2019
Record last verified: 2019-03